Perceptive Advisors LLC boosted its position in shares of Quotient Ltd (NASDAQ:QTNT) by 61.9% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 6,033,020 shares of the company’s stock after acquiring an additional 2,306,034 shares during the quarter. Quotient accounts for approximately 1.0% of Perceptive Advisors LLC’s investment portfolio, making the stock its 25th biggest position. Perceptive Advisors LLC owned 13.23% of Quotient worth $29,683,000 at the end of the most recent quarter.
A number of other institutional investors have also recently made changes to their positions in QTNT. New York State Common Retirement Fund purchased a new position in Quotient during the 2nd quarter valued at about $101,000. Goldman Sachs Group Inc. purchased a new position in Quotient during the 2nd quarter valued at about $104,000. Nationwide Fund Advisors purchased a new position in Quotient during the 2nd quarter valued at about $111,000. Wells Fargo & Company MN boosted its holdings in Quotient by 1,722.9% during the 4th quarter. Wells Fargo & Company MN now owns 33,961 shares of the company’s stock valued at $168,000 after acquiring an additional 32,098 shares during the period. Finally, The Manufacturers Life Insurance Company purchased a new position in Quotient during the 2nd quarter valued at about $177,000. Institutional investors own 68.77% of the company’s stock.
Quotient Ltd (NASDAQ:QTNT) opened at $5.47 on Monday. Quotient Ltd has a twelve month low of $2.78 and a twelve month high of $7.74. The company has a quick ratio of 1.65, a current ratio of 2.34 and a debt-to-equity ratio of 22.54.
In related news, Director Brian Mcdonough purchased 10,000 shares of Quotient stock in a transaction on Thursday, February 8th. The shares were bought at an average price of $3.87 per share, with a total value of $38,700.00. Following the transaction, the director now directly owns 47,747 shares of the company’s stock, valued at $184,780.89. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Prondzynski Heino Von purchased 12,000 shares of Quotient stock in a transaction on Wednesday, February 21st. The stock was bought at an average cost of $4.28 per share, for a total transaction of $51,360.00. The disclosure for this purchase can be found here. Company insiders own 29.00% of the company’s stock.
Quotient Limited is a diagnostics company. The Company focuses on blood grouping and donor disease screening, which is referred to as transfusion diagnostics. It is engaged in developing, manufacturing and commercializing conventional reagent products used for blood grouping within the global transfusion diagnostics market.
Receive News & Ratings for Quotient Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quotient and related companies with MarketBeat.com's FREE daily email newsletter.